Emerging Variants of Castration-Resistant Prostate Cancer

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2017 Apr 1

PMID 28361223

Citations 114

Authors

Panagiotis J Vlachostergios

Loredana Puca

Himisha Beltran

Affiliations

Soon will be listed here.

Abstract

Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical, pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor (AR) signaling, which has clinical implications for patient selection for AR-directed approaches. However, histologic and clinical resistance phenotypes can emerge after AR inhibition, in which the tumors become less dependent on the AR. In this review, we discuss prostate cancer variants including neuroendocrine (NEPC) and aggressive variant (AVPC) prostate cancers and their clinical implications. Improvements in the understanding of the biologic mechanisms and molecular features underlying prostate cancer variants may help prognostication and facilitate the development of novel therapeutic approaches for subclasses of patient with CRPC.

Citing Articles

Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.

Fanelli G, Nuzzo P, Pederzoli F, Loda M Surg Pathol Clin. 2025; 18(1):25-39.

PMID: 39890307 PMC: 11787547. DOI: 10.1016/j.path.2024.10.003.

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer.

Zhu Z, Xuan W, Wang C, Li C Front Oncol. 2024; 14:1481777.

PMID: 39655078 PMC: 11625809. DOI: 10.3389/fonc.2024.1481777.

Triple Tracer PET in Advanced Prostate Cancer: Chasing Phenotypic Plasticity.

Urso L, Brunelli M, Filippi L Mol Diagn Ther. 2024; 29(1):5-8.

PMID: 39621290 DOI: 10.1007/s40291-024-00760-8.

Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer.

Liu S, Garcia-Marques F, Shen M, Bermudez A, Pitteri S, Stoyanova T Am J Clin Exp Urol. 2024; 12(5):306-322.

PMID: 39584005 PMC: 11578776. DOI: 10.62347/JNBR1463.

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Pouliot F, Saad F, Rousseau E, Richard P, Zamanian A, Probst S J Nucl Med. 2024; 65(11):1710-1717.

PMID: 39327017 PMC: 11533914. DOI: 10.2967/jnumed.124.268020.

References

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

Zong Y, Goldstein A . Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol. 2012; 10(2):90-8. DOI: 10.1038/nrurol.2012.237. View

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

Meulenbeld H, Bleuse J, Vinci E, Raymond E, Vitali G, Santoro A . Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int. 2012; 111(1):44-52. DOI: 10.1111/j.1464-410X.2012.11404.x. View

Punnoose E, Ferraldeschi R, Szafer-Glusman E, Tucker E, Mohan S, Flohr P . PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer. 2015; 113(8):1225-33. PMC: 4647881. DOI: 10.1038/bjc.2015.332. View

Han B, Mehra R, Suleman K, Tomlins S, Wang L, Singhal N . Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009; 22(9):1176-85. PMC: 2760291. DOI: 10.1038/modpathol.2009.79. View

Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D . Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer. 2015; 112(7):1166-74. PMC: 4385957. DOI: 10.1038/bjc.2015.63. View

Scher H, Heller G, Molina A, Attard G, Danila D, Jia X . Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33(12):1348-55. PMC: 4397279. DOI: 10.1200/JCO.2014.55.3487. View

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Nakazawa M . Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015; 1(5):582-91. PMC: 4537351. DOI: 10.1001/jamaoncol.2015.1341. View

10.

Zhang X, Coleman I, Brown L, True L, Kollath L, Lucas J . SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015; 21(20):4698-708. PMC: 4609255. DOI: 10.1158/1078-0432.CCR-15-0157. View

11.

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

12.

Scheble V, Braun M, Wilbertz T, Stiedl A, Petersen K, Schilling D . ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010; 56(7):937-43. DOI: 10.1111/j.1365-2559.2010.03564.x. View

13.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

14.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

15.

Mounir Z, Lin F, Lin V, Korn J, Yu Y, Valdez R . TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2014; 34(29):3815-25. DOI: 10.1038/onc.2014.308. View

16.

Aparicio A, Harzstark A, Corn P, Wen S, Araujo J, Tu S . Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19(13):3621-30. PMC: 3699964. DOI: 10.1158/1078-0432.CCR-12-3791. View

17.

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

18.

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

19.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

20.

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View